Recombinant influenza H1, H5 and H9 hemagglutinins containing replaced H3 hemagglutinin transmembrane domain showed enhanced heterosubtypic protection in mice

Vaccine

Volumn 32, Issue 25, 2014, Pages 3041-3049

  Liu, Qiliang ^a   Liu, Kang ^a   Xue, Chunyi ^a   Zhou, Jianqiang ^a   Li, Xiaoming ^a   Luo, Dongyu ^a   Zheng, Jing ^a   Xu, Shun ^a   Liu, George Dacai ^b   Cao, Yongchang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b Firstline Biopharmaceuticals Corporation   (United States)

Author keywords

Hemagglutinin; Immune response; Influenza A virus; Subunit vaccine

Indexed keywords

INFLUENZA H1 HEMAGGLUTININ; INFLUENZA H3 HEMAGGLUTININ; INFLUENZA H5 HEMAGGLUTININ; INFLUENZA H9 HEMAGGLUTININ; INFLUENZA VIRUS HEMAGGLUTININ; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; FEMALE; HEMAGGLUTINATION INHIBITION; HETEROPROTECTION; IMMUNITY; IMMUNIZATION; INFLUENZA A VIRUS (A/PUERTO RICO/8/1934(H1N1)); INFLUENZA VIRUS A H9N2; INSECT CELL; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SITE DIRECTED MUTAGENESIS; SURVIVAL RATE; THERMOSTABILITY;

HEMAGGLUTININ; IMMUNE RESPONSE; INFLUENZA A VIRUS; SUBUNIT VACCINE;

AMINO ACID SEQUENCE; ANIMALS; CROSS PROTECTION; CYTOKINES; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H9N2 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; MUTATION; ORTHOMYXOVIRIDAE INFECTIONS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SF9 CELLS;

EID: 84899967464     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.03.058     Document Type: Article

References (35)

1. Morens D.M., Taubenberger J.K., Fauci A.S. Pandemic influenza viruses - hoping for the road not taken. N Engl J Med 2013, 368:2345-2348.
2. Pica N., Palese P. Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med 2013, 64:189-202.
3. Goldenberg M.M. Pharmaceutical approval update. P T. 2013, 38:150-152.
4. Couch R.B. Seasonal inactivated influenza virus vaccines. Vaccine 2008, 26(Suppl. 4):D5-D9.
5. Li Q., Zhou L., Zhou M., Chen Z., Li F., Wu H., et al. Preliminary report: epidemiology of the Avian Influenza A (H7N9) outbreak in China. N Engl J Med 2013, 370:520-532.
6. Salomon R., Webster R.G. The influenza virus enigma. Cell 2009, 136:402-410.
7. Bouvier N.M., Palese P. The biology of influenza viruses. Vaccine 2008, 26(Suppl. 4):D49-D53.
8. Tong S., Li Y., Rivailler P., Conrardy C., Castillo D.A., Chen L.M., et al. A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci USA 2012, 109:4269-4274.
9. Tong S., Zhu X., Li Y., Shi M., Zhang J., Bourgeois M., et al. New world bats harbor diverse influenza A viruses. PLoS Pathog 2013, 9:e1003657.
10. Treanor J.J., Schiff G.M., Hayden F.G., Brady R.C., Hay C.M., Meyer A.L., et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 2007, 297:1577-1582.
11. Cox M.M., Hollister J.R. FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals 2009, 37:182-189.
12. Subbarao K., Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol 2007, 7:267-278.
13. Nabel G.J., Fauci A.S. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med 2010, 16:1389-1391.
14. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999, 5:1157-1163.
15. Wang T.T., Tan G.S., Hai R., Pica N., Petersen E., Moran T.M., et al. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog 2010, 6:e1000796.
16. Ulmer J.B., Valley U., Rappuoli R. Vaccine manufacturing: challenges and solutions. Nat Biotechnol 2006, 24:1377-1383.
17. Du L., Leung V.H., Zhang X., Zhou J., Chen M., He W., et al. A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses. PLoS One 2011, 6:e16555.
18. Weldon W.C., Wang B.Z., Martin M.P., Koutsonanos D.G., Skountzou I., Compans R.W. Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One 2010, 5.
19. Kanekiyo M., Wei C.J., Yassine H.M., McTamney P.M., Boyington J.C., Whittle J.R., et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 2013, 499:102-106.
20. Xu S., Zhou J., Liu K., Liu Q., Xue C., Li X., et al. Mutations of two transmembrane cysteines of hemagglutinin (HA) from influenza A H3N2 virus affect HA thermal stability and fusion activity. Virus Genes 2013, 47:20-26.
21. Li J., Ulitzky L., Silberstein E., Taylor D.R., Viscidi R. Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates. Viral Immunol 2013, 26:126-132.
22. Jegaskanda S., Job E.R., Kramski M., Laurie K., Isitman G., de Rose R., et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol 2013, 190:1837-1848.
23. Chen J.X., Xue H.J., Ye W.C., Fang B.H., Liu Y.H., Yuan S.H., et al. Activity of andrographolide and its derivatives against influenza virus in vivo and in vitro. Biol Pharm Bull 2009, 32:1385-1391.
24. Qiao C., Tian G., Jiang Y., Li Y., Shi J., Yu K., et al. Vaccines developed for H5 highly pathogenic avian influenza in China. Ann N Y Acad Sci 2006, 1081:182-192.
25. Hagedorn M., Neuhaus E.M., Soldati T. Optimized fixation and immunofluorescence staining methods for Dictyostelium cells. Methods Mol Biol 2006, 346:327-338.
26. van Drunen L., van den Hurk S., Parker M.D., Fitzpatrick D.R., Zamb T.J., van den Hurk J.V., et al. Expression of bovine herpesvirus 1 glycoprotein gIV by recombinant baculovirus and analysis of its immunogenic properties. J Virol 1991, 65:263-271.
27. Wang S., Taaffe J., Parker C., Solorzano A., Cao H., Garcia-Sastre A., et al. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J Virol 2006, 80:11628-11637.
28. Park P.S., Wells J.W. Monomers and oligomers of the M2 muscarinic cholinergic receptor purified from Sf9 cells. Biochemistry 2003, 42:12960-12971.
29. Pushko P., Tumpey T.M., Bu F., Knell J., Robinson R., Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005, 23:5751-5759.
30. Miller D.S., Kok T., Li P. The virus inoculum volume influences outcome of influenza A infection in mice. Lab Anim-UK 2013, 47:74-77.
31. Kang S.M., Guo L., Yao Q., Skountzou I., Compans R.W. Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens. J Virol 2004, 78:9624-9632.
32. Quan F.S., Huang C., Compans R.W., Kang S.M. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 2007, 81:3514-3524.
33. Lin S.C., Huang M.H., Tsou P.C., Huang L.M., Chong P., Wu S.C. Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines. PLoS One 2011, 6:e20052.
34. Pepin S., Donazzolo Y., Jambrecina A., Salamand C., Saville M. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine 2013, 31:5572-5578.
35. Lee Y.T., Kim K.H., Ko E.J., Lee Y.N., Kim M.C., Kwon Y.M., et al. New vaccines against influenza virus. Clin Exp Vaccine Res 2014, 3:12-28.